How to manage individualized drug therapy: Application of pharmacogenetic knowledge of drug metabolism and transport

Clinical Chemistry and Laboratory Medicine

Volumn 38, Issue 9, 2000, Pages 869-876

  Meisel, Christian ^a   Roots, Ivar ^a   Cascorbi, Ingolf ^b   Brinkmann, Ulrich ^c   Brockmöller, Jürgen ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

^c Epidauros Biotechnologie AG   (Germany)

Author keywords

Drug metabolizing enzymes; Drug transporters; P glycoprotein; Pharmacogenetics; Polymorphisms

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AJMALINE; AMITRIPTYLINE; CARVEDILOL; CODEINE; DEBRISOQUINE 4 HYDROXYLASE; DESIPRAMINE; DRUG; ENCAINIDE; FLECAINIDE; FLUOXETINE; FLUVOXAMINE; GALANTAMINE; HALOPERIDOL; METHAMPHETAMINE; METOPROLOL; MEXILETINE; NORTRIPTYLINE; PERAZINE; PERPHENAZINE; PRAJMALINE; PROPAFENONE; PROPRANOLOL; RISPERIDONE; SPARTEINE; THIORIDAZINE; TIMOLOL; TRAMADOL; TROPISETRON; UNINDEXED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG RESPONSE; DRUG THERAPY; DRUG TRANSPORT; ENZYME ACTIVITY; GENETIC POLYMORPHISM; GENOTYPE; HEREDITY; HUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; TREATMENT PLANNING;

EID: 0033754363     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2000.126     Document Type: Article

References (58)

1. Frequency and cost of serious adverse drug reactions in a department of general medicine
2. Counting the costs of drug-related adverse events
3. Molecular basis of polymorphic drug metabolism
4. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine
5. Cytochrome P450 2D6 variants in a Caucasian population: Allele frequencies and phenotypic consequences
6. Correctness of prediction of the CYP2D6 phenotype confirmed by genotyping 47 intermediate and poor metabolizers of debrisoquine
7. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D19 and 2D6 in the Turkish population
8. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions
9. Impact of environmental and genetic factors on codeine analgesia
10. Codeine and morphine in extensive and poor metabolizers of sparteine: Pharmacokinetics, analgesic effect and side effects
11. Quick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquine
12. Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity
13. Polymorphism of the thiopurine S-methyltrans-ferase gene in African-Americans
14. Human thiopurine methyl-transferase pharmacogenetics: Gene sequence polymorphisms
15. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia
16. Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia
17. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease
18. Childhood leukaemia: A relationship between intracellular 6-mercaptopurine metabolites and neutropenia
19. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient
20. Molecular diagnosis of thiopurine S-methyl-transferase deficiency: Genetic basis for azathioprine and mercaptopurine intolerance
21. Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier
22. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins
23. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors
24. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin
25. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
26. Biochemical, cellular, and pharmacological aspects of the multidrug transporter
27. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum)
28. Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment
29. Correlation between genotype and phenotype of the human arylamine N-acetyltransferase type 1 (NAT1)
30. Arylamine N-acetyltransferase activity in man
31. Pitfalls in N-acetyltransferase 2 genotyping
32. Association of arylamine N-acetyltransferases NAT1 and NAT2 genotypes to laryngeal cancer risk
33. Arylamine N-acetyltransferase (NAT2) genotypes in a Turkish population
34. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: Correlation with phenotypic activity
35. Polymorphic human cytochrome P450 enzymes: An opportunity for individualized drug treatment
36. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin
37. Simultaneous assessment of CYP3A4 and CYP1A2 activity in vivo with alprazolam and caffeine
38. Drug-mediated toxicity caused by genetic deficiency of UDP-glucuronosyltransferases
39. Flavin monooxygenase 3 (FMO3) polymorphism in a white population: Allele frequencies, mutation linkage, and functional effects on clozapine and caffeine metabolism
40. Genetic polymorphism of human liver alcohol and aldehyde dehydrogenases, and their relationship to alcohol metabolism and alcoholism
41. Glutathione S-transferase: Genetics and role in toxicology
42. Detection of the GSTM1*0 allele by long polymerase chain reaction
43. Concordance between enzyme activity and genotype of glutathione S-transferase theta (GSTT1)
44. Combined analysis of inherited polymorphisms in arylamine N-acetyl-transferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk
45. Substantially reduced risk of cancer of the aerodigestive tract in subjects with variant-463A of the myeloperoxidase gene
46. Methylation pharmacogenetics: Catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyl-transferase
47. Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase enzymes: Relevance to xenobiotic metabolism and toxicity
48. Major gene polymorphism for human erythrocyte (RBC) thiol methyltransferase (TMT)
49. Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy
50. DNA mutation associated with the human butyrylcholinesterase K-variant and its linkage to the atypical variant mutation and other polymorphic sites
51. Mutations in the human paraoxonase 1 gene: Frequencies, allelic linkages, and association with coronary artery disease
52. Paraoxonase 1 mutations in a Turkish population
53. Pharmacogenetics of sulfotransferase
54. Diagnostic analysis, clinical importance and molecular basis of dihydropyrimidine dehydrogenase deficiency
55. Identification of the human cytochromes P450 involved in the oxidative metabolism of ″Ecstasy″-related designer drugs
56. The O-demethylation of the antidementia drug galanthamine is catalysed by cytochrome P450 2D6
57. Pharmacokinetics of N-propylajmaline in relation to polymorphic sparteine oxidation
58. Oxidation of methamphetamine and methylenedioxymethamphetamine by CYP2D6